NCT00003452View on ClinicalTrials.gov

Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

May 6, 1996

Primary Completion Date

May 4, 1998

Study Completion Date

May 4, 1998

Conditions
Stage IV Bladder Cancer
Interventions
DRUG

Antineoplaston therapy (Atengenal + Astugenal)

"Patients with Stage IV Bladder Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."

Trial Locations (1)

77055-6330

Burzynski Clinic, Houston

Sponsors
All Listed Sponsors
lead

Burzynski Research Institute

OTHER